• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 2, 2017

View Archived Issues

Financings

Aptevo Therapeutics Inc., of Seattle, said it amended the terms of a credit agreement initially executed with Midcap Financial Trust in August last year. Read More

Other news to note

Affigen LLC, of St. Louis, and CCRM, a Canadian not-for-profit organization funded by the Canadian government, the Province of Ontario and leading academic and industry partners to support regenerative medicines and associated enabling technologies, said they partnered to create and commercialize a closed platform for the production of individualized, tumor-identifying therapeutics for the treatment of a range of currently incurable cancers. Read More

In the clinic

Prothena Corp. plc, of Dublin, reported results from a phase Ib multiple ascending dose trial testing PRX003 in 33 patients with psoriasis. PRX003, a monoclonal antibody targeting CD146 that's expressed on T helper 17 cells (Th17), didn't produce meaningful clinical benefit as measured by responses in the Psoriasis Area and Severity Index 75. Read More

Bench Press: BioWorld looks at translational medicine

The epithelial to mesenchymal transition (EMT) is a dedifferentiation process that occurs in tumor cells as they become more invasive. It has also been implicated as an important process in dedifferentiation that occurs during the generation of induced pluripotent stem cells (iPSCs). Read More

Peptilogics using 'rational engineering' to pursue MDR pathogens

A year after its seed financing, Peptilogics Inc. closed a $5.5 million series A to advance its engineered cationic antibiotic peptide, or ECAP, platform to ply multidrug-resistant (MDR) bacterial infections. The ECAP mechanism enables direct targeting and disruption of bacterial membranes without lysing, causing rapid death of both dormant and growing bacterial cells. Read More

Let Freedom-Ev ring, later; DMC's United edict means trial still on as PAH evolves

Although trading nipped shares of United Therapeutics Corp. when the news broke, few onlookers likely felt shock when the data monitoring committee (DMC) decreed earlier this month that the company keep going with its Freedom-Ev trial testing vasodilator Orenitram (treprostinil extended-release tablets). Read More

New method maps long-range gene regulation

In findings with implications for both drug discovery and cell fate, researchers have developed a method to map regulatory elements called enhancers to their target genes. Read More

From biology to platforms to drugs: Astellas approach limiting, but in useful ways

BOSTON – At last week's Biopharm America meeting, Astellas Pharma Inc.'s Salim Mujais sat down with BioWorld for a high-level look at the Tokyo-based firm's efforts in therapeutic areas outside of cancer. Read More

Survey says: Amsterdam favored as next EMA home

LONDON – And the votes are in: Amsterdam is the city most favored by the EMA's 890 staff as the new home for the agency when it relocates from London after Brexit. Read More

Zogenix shares soar on strong pivotal Dravet data

Positive new pivotal data has shown that ZX-008, Zogenix Inc.'s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe